Abstracts related to all areas of ketamine treatment - (biology, psychopharmacology, mechanism of action, treatment protocols or ketamine assisted psychotherapy) will be considered for either a short 15 minute presentation or poster presentation. Unpublished findings and reviews of clinical experience are welcome. ASKP3 invites submission of abstracts related to the use of ketamine, or related compounds, for the treatment of psychiatric conditions, pain, or substance use disorders. Abstracts should describe findings from clinical practice or research. Authors of selected abstracts will be invited to give a 15 minute oral presentation or to give a poster presentation. The abstract will be printed in the conference proceedings. Not all abstracts can be selected. Selection criteria include novelty and significance for clinical practice. Abstracts must be submitted through the conference registration page by June 15, 2021 at 5pm Eastern Time. The abstract length is limited to 5000 characters.